FDA rejects gender bias charge; Kamada rises on lung drug hopes;

@FierceBiotech: As many as 5 life sciences companies could go public this week, bringing in a combined $115M. News | Follow @FierceBiotech

@JohnCFierce: Really enjoyed talking with One Nucleus members about biotech valuations. Interesting times. | Follow @JohnCFierce

@DamianFierce: The most influential people in biopharma today, according to FierceBiotech. Who'd we miss? Who doesn't belong? | Follow @DamianFierce

@EmilyMFierce: Penn cancer research Carl June made our list of most influential people in biopharma. Profile | Follow @EmilyMFierce

> After last year's rejection of a treatment for female hypoactive sexual desire disorder, the FDA has faced charges of carrying on a gender bias in its approach to libido drugs. Now the agency has fired back, telling Reuters it does not discriminate and has only "engaged in a scientific process in which we evaluated whether the drug's benefits outweigh its risk." More

> Israel's Kamada ($KMDA), a 2013 IPO alum, has seen its shares steadily rise as investors await the results of a Phase II study on its drug for hereditary lung disease. Article

Medical Device News

@FierceMedDev: Italian Dx outfit DiaSorin launched a new Rotavirus test in the EU - it could have legs in the developing world, too. Story | Follow @FierceMedDev

@MarkHFierce: Folks, we have a strong new issue of FierceDiagnostics ready for reading. News from Myriad, Brazil and more. Issue | Follow @MarkHFierce

@MichaelGFierce: Who are the most influential people in biopharma today? Check out FierceBiotech's 2014 list. Report | Follow @MichaelGFierce

@EmilyWFierce: King Richard III's genome to be sequenced by researchers at the University of Leicester. Article | Follow @EmilyWFierce

> FDA publishes its warning letter to Baxter over home dialysis and infusion devices. Story

> NC patients exposed to rare, fatal brain disease through dirty surgical tools. More

> Sequoia Capital leads $10M round for cancer Dx startup Guardant Health. Item

> The FDA hit Amgen with a warning over drug/device combo manufacturing violations. News

Pharma News

@FiercePharma: AstraZeneca's stateside comeback for Brilinta has run aground on a DoJ investigation. Story | Follow @FiercePharma

@TracyStaton: Team effort here - The most influential people in biopharma today. Report | Follow @TracyStaton

@EricPFierce: Hospira CEO F. Michael Ball says the FDA has moved its Austin, TX and Rocky Mount, NC facilities to VAI status. | Follow @EricPFierce

@CarlyHFierce: Can't make an influentials list without Valeant CEO J. Michael Pearson - that M&A strategy has made waves. More | Follow @CarlyHFierce

> Gilead backs exuberant analyst projections for new hep C drug. News

> Novartis aims for super-speed with strategic review, CEO tells analysts. Piece

> FDA panel says Aleve should keep its heart-risk warning. Story

Drug Delivery News

> CalTech: Antibody carriers grant HIV protection across mucosal membranes. More

> To fight muscular dystrophy, nanoparticles target cells that choke themselves with waste. Story

> BioDelivery looks for $60M offering to boost addiction film, pain gel. News

> Alnylam, MIT team develops RNA-delivering nanoparticles for the liver. Report

> Nasal vaccine delivery conquers West Nile Virus in fewer doses. Article

> Sonrgy grabs rights to UCSD-created ultrasound-nanocarrier tech. Item

Diagnostics News

> Guardant Health raises $10M and debuts a new blood Dx for personalized cancer treatment. Story

> One Brazilian Dx giant gets new majority shareholders, and another may be sold. News

> Scottish imaging agent startup raises a $6.56 million Series A round. More

> Myriad and Gene By Gene resolve their differences over BRCA cancer Dx tests. Article

> Exact will make its case on March 27 for FDA approval of a colon cancer Dx. Piece

> Alere improves Q4 numbers through revenue growth and cost cuts. Item

Pharma Marketing News

> Steering for a U.S. comeback, AstraZeneca's Brilinta runs aground on DoJ investigation. Story

> Will PBMs turn copay coupons into an endangered species? Article

> Big Pharma legal whiz sees DoJ, FDA crackdown on CEO quotes and press releases. Story

> Feds target Teva in probe of Copaxone, Azilect marketing. News

> Nestlé plans to use its global marketing juju to rev up Galderma. Article

> New NICE advice could put millions more U.K. patients on statins. Item

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.